The role of type I interferons and other cytokines in dermatomyositis

Cytokine

Volumn 73, Issue 2, 2015, Pages 319-325

  Arshanapalli, Ashish ^a   Shah, Mihir ^b   Veerula, Vindhya ^a   Somani, Ally Khan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Cytokines; Dermatomyositis; Inflammatory myopathy; Pathogenesis; Type I interferons

Indexed keywords

AUTOANTIBODY; INTERFERON;

BIOLOGICAL MODEL; DERMATOMYOSITIS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

AUTOANTIBODIES; DERMATOMYOSITIS; HUMANS; INTERFERON TYPE I; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 84939943181     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.026     Document Type: Article

References (98)

1. Bolognia J.L., Schaffer J.V. Dermatology 2012, Elsevier Saunders. 3rd ed.
2. Sontheimer R.D. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002, 20:387-408.
3. Schwarz H.A., Slavin G., Ward P., Ansell B.M. Muscle biopsy in polymyositis and dermatomyositis: a clinicopathological study. Ann Rheum Dis 1980, 39:500-507.
4. Di Rollo D., Abeni D., Tracanna M., Capo A., Amerio P. Cancer risk in dermatomyositis: a systematic review of the literature. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia 2014.
5. Greenberg S.A. Inflammatory myopathies: evaluation and management. Semin Neurol 2008, 28:241-249.
6. Strauss K.W., Gonzalez-Buritica H., Khamashta M.A., Hughes G.R. Polymyositis-dermatomyositis: a clinical review. Postgrad Med J 1989, 65:437-443.
7. Tymms K.E., Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985, 12:1140-1148.
8. Reichlin M., Arnett F.C. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984, 27:1150-1156.
9. Santmyire-Rosenberger B., Dugan E.M. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003, 15:714-722.
10. Dalakas M.C. Muscle biopsy findings in inflammatory myopathies. Rheumatic Diseases Clinics North America 2002, 28:779-798.
11. Bergman R., Sharony L., Schapira D., Nahir M.A., Balbir-Gurman A. The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 2003, 139:1027-1030.
12. Buchanan I.S., Humpston D.J. Nail-fold capillaries in connective-tissue disorders. Lancet 1968, 1:845-847.
13. Iorizzo L.J., Jorizzo J.L. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008, 59:99-112.
14. Femia A.N., Eastham A.B., Lam C., Merola J.F., Qureshi A.A., Vleugels R.A. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol 2013, 69:654-657.
15. Somani A.K., Swick A.R., Cooper K.D., McCormick T.S. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008, 144:1341-1349.
16. Alazemi S., Campos M.A. Interferon-induced sarcoidosis. Int J Clin Pract 2006, 60:201-211.
17. Houglum J.E. Interferon: mechanisms of action and clinical value. Clin Pharm 1983, 2:20-28.
18. Baccala R., Hoebe K., Kono D.H., Beutler B., Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007, 13:543-551.
19. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
20. Baccala R., Kono D.H., Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005, 204:9-26.
21. Taniguchi T., Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002, 14:111-116.
22. Uddin S., Platanias L.C. Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 2004, 37:635-641.
23. Burdick L.M., Somani N., Somani A.K. Type I IFNs and their role in the development of autoimmune diseases. Expert Opinion Drug Safety 2009, 8:459-472.
24. Borden E.C., Sen G.C., Uze G., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discovery 2007, 6:975-990.
25. Marzouk K., Saleh S., Kannass M., Sharma O.P. Interferon-induced granulomatous lung disease. Current Opinion Pulmonary Medicine 2004, 10:435-440.
26. Wenzel J., Tuting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis". J Invest Dermatol 2008, 128:2392-2402. Epub April 17. 10.1038/jid.2008.96.
27. Magro C.M., Segal J.P., Crowson A.N., Chadwick P. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 2009 Nov 4, 2010(37):659-671. 10.1111/j.600-0560.2009.01443.x. Epub.
28. Wenzel J., Schmidt R., Proelss J., Zahn S., Bieber T., Type Tuting T., et al. Interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006, 31:576-582.
29. McNiff J.M., Kaplan D.H. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol 2008, 35:452-456. Epub 2007 November 12.
30. Sontheimer R.D. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009, 129:1088-1099. Epub February 26. 10.38/sj.jid.2009.42.
31. Greenberg S.A., Pinkus J.L., Pinkus G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
32. Lopez de Padilla C.M., Vallejo A.N., McNallan K.T., et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007, 56:1658-1668.
33. Chen S.C., de Groot M., Kinsley D., et al. Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 2009 Jun 11, 2010(302):113-123. 10.1007/s00403-009-0966-2. Epub.
34. Varughese N., Petrella T., Singer M., Carlson J.A. Plasmacytoid (CD68+CD123+) monocytes may play a crucial role in the pathogenesis of hydroa vacciniforme: a case report. Am J Dermatopathol 2009, 31:828-833. 10.1097/DAD.0b013e3181a8527f.
35. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
36. Liao A.P., Salajegheh M., Morehouse C., et al. Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production. Clin Immunol 2010, 136:130-138. Epub March 25. 10.1016/j.clim.2010.02.014.
37. Kim G.T., Cho M.L., Park Y.E., et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 2009, 2010(29):273-279. Epub 2009 December 2. 10.1007/s10067-009-1316-7.
38. Cappelletti C., Baggi F., Zolezzi F., et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011, 76:2079-2088. 10.1212/WNL.0b013e31821f440a.
39. Kadowaki N., Antonenko S., Lau J.Y., Liu Y.J. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000, 192:219-226.
40. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Safety: an International Journal of Medical Toxicology and Drug Experience 1994, 10:115-150.
41. Horton C.G., Pan Z.J., Farris A.D. Targeting Toll-like receptors for treatment of SLE. Mediat Inflam 2010, 498980. Epub 2010 September 19. 10.1155/2010.
42. Greenberg S.A., Amato A.A. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004, 17:359-364.
43. Salajegheh M., Kong S.W., Pinkus J.L., et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010, 67:53-63. 10.1002/ana.21805.
44. Walsh R.J., Kong S.W., Yao Y., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784-3792.
45. Greenberg S.A. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007, 19:536-541.
46. Tezak Z., Hoffman E.P., Lutz J.L., et al. Gene expression profiling in DQA1 0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154-4163.
47. Chen Y.W., Shi R., Geraci N., Shrestha S., Gordish-Dressman H., Pachman L.M. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol 2008, 9:43. 10.1186/471-2172-9-4.
48. Bilgic H., Ytterberg S.R., Amin S., et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60:3436-3446.
49. Baechler E.C., Bauer J.W., Slattery C.A., et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59-68.
50. Wong D., Kea B., Pesich R., et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS ONE 2012, 7:e29161.
51. Walsh R.J., Kong S.W., Yao Y., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784-3792.
52. Liao A.P., Salajegheh M., Nazareno R., Kagan J.C., Jubin R.G., Greenberg S.A. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011, 70:831-836.
53. Nousari H.C., Kimyai-Asadi A., Tausk F.A. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998, 352:1825-1826.
54. Gao S., von der Malsburg A., Dick A., et al. Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity 2011, 35:514-525.
55. Wenzel J., Worenkamper E., Freutel S., et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005, 205:435-442.
56. O'Connor K.A., Abbott K.A., Sabin B., Kuroda M., Pachman L.M. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006, 120:319-325.
57. Suarez-Calvet X., Gallardo E., Nogales-Gadea G., et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 2014, 233:258-268.
58. Yoneyama M., Kikuchi M., Natsukawa T., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
59. Hornung V., Ellegast J., Kim S., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
60. Kato H., Takeuchi O., Mikamo-Satoh E., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008, 205:1601-1610.
61. Greenberg S.A. Sustained autoimmune mechanisms in dermatomyositis. J Pathol 2014, 233:215-216.
62. Nakashima R., Imura Y., Kobayashi S., et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 2010, 49:433-440.
63. Sato S., Hoshino K., Satoh T., et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009, 60:2193-2200.
64. Chistiakov D.A. Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol 2010, 23:3-15.
65. Ikegame S., Takeda M., Ohno S., Nakatsu Y., Nakanishi Y., Yanagi Y. Both RIG-I and MDA5 RNA helicases contribute to the induction of alpha/beta interferon in measles virus-infected human cells. J Virol 2010, 84:372-379.
66. Caproni M., Torchia D., Cardinali C., et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. British J Dermatol 2004, 151:784-791.
67. De Paepe B., Creus K.K., De Bleecker J.L. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci 2007, 1109:441-453.
68. Civatte M., Bartoli C., Schleinitz N., Chetaille B., Pellissier J.F., Figarella-Branger D. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005, 31:70-79.
69. Confalonieri P., Bernasconi P., Megna P., Galbiati S., Cornelio F., Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000, 59:164-169.
70. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., Schroder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 2002, 58:1779-1785.
71. Liprandi A., Bartoli C., Figarella-Branger D., Pellissier J.F., Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol 1999, 97:642-648.
72. Jain A., Sharma M.C., Sarkar C., et al. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand 2011, 123:122-129.
73. Kissel J.T., Halterman R.K., Rammohan K.W., Mendell J.R. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991, 48:26-30.
74. Kissel J.T., Mendell J.R., Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. New Engl J Med 1986, 314:329-334.
75. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
76. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343-356.
77. Kissel J.T., Mendell J.R., Rammohan K.W. Microvascular deposition of complement membrane attack complex. New Engl J Med 1986, 314:329-334.
78. De Rossi M., Bernasconi P., Baggi F., de Waal Malefyt R., Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000, 12:1329-1335.
79. Adams E.M., Kirkley J., Eidelman G., Dohlman J., Plotz P.H. The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997, 109:275-285.
80. Knight E. Antiviral and cell growth inhibitory activities reside in the same glycoprotein of human fibroblast interferon. Nature 1976, 262:302-303.
81. Baeten D.L., Kuchroo V.K. How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med 2013, 19:824-825.
82. Page G., Chevrel G., Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004, 50:199-208.
83. Szodoray P., Alex P., Knowlton N., et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology 2010, 49:1867-1877.
84. Higgs B.W., Zhu W., Richman L., et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Diseases 2012, 15:25-35.
85. Tang X., Tian X., Zhang Y., et al. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol 2013, 2013:345347.
86. Tournadre A., Lenief V., Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 2010, 62:2144-2151.
87. Chevrel G., Page G., Granet C., Streichenberger N., Varennes A., Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003, 137:125-133.
88. Scuderi F., Mannella F., Marino M., Provenzano C., Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 2006, 176:9-15.
89. Gunawardena H., Betteridge Z.E., McHugh N.J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 2009, 48:607-612.
90. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Ronnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
91. Labrador-Horrillo M., Martinez M.A., Selva-O'Callaghan A., et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014, 2014:290797.
92. Fiorentino D., Chung L., Zwerner J., Rosen A., Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011, 65:25-34.
93. Targoff I.N., Mamyrova G., Trieu E.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
94. Balboni I., Niewold T.B., Morgan G., et al. Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum 2013, 65:2424-2429.
95. Venalis P., Lundberg I.E. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology 2014, 53:397-405.
96. Higgs B.W., Zhu W., Morehouse C., et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014, 73:256-262.
97. Narazaki M., Hagihara K., Shima Y., Ogata A., Kishimoto T., Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 2011, 50:1344-1346.
98. Okiyama N., Sugihara T., Iwakura Y., Yokozeki H., Miyasaka N., Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009, 60:2505-2512.